A threat to medical innovation

Science

Volumn 333, Issue 6039, 2011, Pages 136-

  Rosbash, Michael ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT DNA;

BIOMEDICINE; BIOTECHNOLOGY; BUDGET; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; EDITORIAL; FINANCIAL MANAGEMENT; GOVERNMENT; MEDICAL SOCIETY; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; RNA INTERFERENCE;

BIOMEDICAL RESEARCH; BUDGETS; FINANCING, GOVERNMENT; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 79960107093     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1210374     Document Type: Editorial

References (3)

1. *NIH Recovery Act Grant Awards: Fiscal Year 2009 spreadsheet (http://report.nih.gov/recovery).
2. † http://report.nih.gov/NIHDatabook/Charts/Default.aspx?showm= Y&chartId=34&catId=2.
3. ‡http://blogs.wsj.com/health/2011/04/15/former-merck-head-vagelos- says-nih-should-stick-to-basic-research.